Journal of Clinical Oncology · 2013 · 194 citations · 26 references
MedicineGeneticsOncologyCancer GeneticsGenitourinary OncologyMedical GeneticsGermline Cancer PredispositionHereditary Cancer SyndromesHereditary Kidney DiseasesHereditary Renal DiseasesKidney CancerRenal Cell CarcinomaAge-specific Diagnostic ThresholdsAge-specific DistributionGenetic TestingGermline Mutation TestingHereditary Kidney Cancer SyndromesHereditary Renal CancerHereditary Renal Cell CancerHereditary Renal Cell Carcinoma
PURPOSE: Approximately 5% to 8% of renal cell carcinoma (RCC) is hereditary. No guidelines exist for patient selection for RCC germline mutation testing. We evaluate how age of onset could indicate the need for germline mutation testing for detection of inherited forms of kidney cancer. PATIENTS AND METHODS: We analyzed the age distribution of RCC cases in the SEER-17 program and in our institutional hereditary kidney cancer population. The age distributions were compared by sex, race, histology, and hereditary cancer syndrome. Models were established to evaluate the specific age thresholds for genetic testing. RESULTS: The median age of patients with RCC in SEER-17 was 64 years, with the distribution closely approaching normalcy. Statistical differences were observed by race, sex, and subtype (P < .05). The bottom decile cutoff was ≤ 46 years of age and slightly differed by sex, race, and histology. The mean and median ages at presentation of 608 patients with hereditary kidney cancer were 39.3 years and 37 years, respectively. Although age varied by specific syndrome, 70% of these cases were found to lie at or below the bottom age decile. Modeling age-based genetic testing thresholds demonstrated that the 10th percentile maximized sensitivity and specificity. CONCLUSION: Early age of onset might be a sign of hereditary RCC. Even in the absence of clinical manifestations and personal/family history, an age of onset of 46 years or younger should trigger consideration for genetic counseling/germline mutation testing and may serve as a useful cutoff when establishing genetic testing guidelines.
26
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2012 · 10.7K citations · Full text
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
Corine Bertolotto, Fabienne Lesueur, Sandy Giuliano et al. · Nature · 2011 · 522 citations
Laura S. Schmidt, Michelle B. Warren, Michael L. Nickerson et al. · The American Journal of Human Genetics · 2001 · 376 citations · Full text
Medicine, Nephrology, Pathology +16